Beneficial effects of different Flavonoids on Vascular and Renal Function in L-NAME Hypertensive Rats

María Dolores Paredes 1, Paola Romeicín 1, Noemí M. Atucha 1, Francisco O’Valle 2, Julián Castillo 3, M. Clara Ortiz 1, and Joaquín García-Estañ 1,*

1 Departamento de Fisiología, Facultad de Medicina & Instituto Murciano de Investigaciones Biosanitarias, Universidad de Murcia, Murcia, Spain
2 Departamento de Patología, Facultad de Medicina, Universidad de Granada, Granada, Spain
3 Instituto Universitario de Envejecimiento & Research and Development Department, Nutrafur SA-FRUTAROM Group, Alcantarilla (Murcia), Spain
* Correspondence: jgestan@um.es; Tel.: +34-868-884-880

Abstract: 1) Background: we have evaluated the antihypertensive effect of several flavonoid extracts in a rat model of arterial hypertension caused by chronic administration (6 weeks) of the nitric oxide synthesis inhibitor, L-NAME. 2) Methods: Sprague Dawley rats received L-NAME alone or L-NAME plus flavonoid-rich vegetal extracts (Lemon, Grapefruit + Bitter Orange, and Cocoa) or purified flavonoids (Apigenin and Diosmin) for 6 weeks. 3) Results: L-NAME treatment resulted in a marked elevation of blood pressure, and treatment with Apigenin, Lemon Extract, and Grapefruit + Bitter Orange extracts significantly reduced the elevated blood pressure of these animals. Apigenin and some of these flavonoids also ameliorated nitric oxide-dependent and independent aortic vasodilation and elevated nitrite urinary excretion. End-organ abnormalities such as cardiac infarcts, hyaline arteriopathy and fibrinoid necrosis in coronary arteries and aorta were improved by these treatments, reducing the end-organ vascular damage. 4) Conclusions: the flavonoids included in this study, specially apigenin, may be used as functional food ingredients with potential therapeutic benefit in arterial hypertension.

Keywords: flavonoids; nitric oxide; heart; kidney; sodium balance; phenylephrine; acetylcholine.

1. Introduction

Animal studies using flavonoid-rich foods are a valid alternative to advance on the comprehension of the mechanisms underlying their hypotensive effects in experimental models of arterial hypertension [1]. The intake of polyphenols has been related with a beneficial effect that reduces the risk of hypertension [2]. In fact, epidemiological studies found that an increased consumption of foods and beverages rich in flavonoids is related to a reduced risk of cardiovascular death [3-4]. Moreover, the use of products with a natural origin that may cause few
side-effects, is an attractive possibility to be considered for the
treatment of several pathologies [5]. Several studies have described
that the consumption of flavonoid-rich food or isolated compounds
improves several cardiovascular parameters such as flow-mediated
dilation and cardiovascular risk biomarkers [6-7]. Additionally, many
flavonoids induce the release of endothelium-derived vasodilatory
factors such as nitric oxide (NO) or endothelium-derived
hyperpolarizing factor (EDHF) and decrease the release of pro-
inflammatory substances, thus inducing an improvement of endothelial
function [8-9].

L-NAME hypertension is a very frequently used model of endothelial
dysfunction. Moreover, since L-NAME administration induces arterial
hypertension, it has been used extensively to analyze the role of NO in
the control of blood pressure [10-12]. The kidney seems to be one of the
first organs that react to the loss of NO, and a reduced pressure
natriuresis response and an enhanced role of the renin-angiotensin
system have been involved in its pathophysiology [10-12]. Arterial
hypertension induced by chronic L-NAME administration is
accompanied with cardiovascular remodeling, very evident in the heart
and also in conduit and resistance vessels. Left ventricular hypertrophy
and myocardial fibrosis [12-13] and thickening of the aortic wall and
remodeling of mesenteric resistance arteries [14] have all been
reported. Recently, down-regulated eNOS protein expression in blood
vessels and depletion of plasma NO levels have been described in L-
NAME-treated rats [15], thus probably contributing, by a reduced
vasorelaxation, to increased vascular resistance and high blood
pressure [16]. Increased levels of oxidative stress markers were also
observed in L-NAME hypertensive rats [14], including peroxynitrite, a
very reactive intermediate and one of the most potent oxidants known
in biological systems, that causes long-lasting impairment of the
vasoactive response to vasodilators [17]. Oxidative stress-derived
products not only decrease NO bioavailability, causing impaired
vasorelaxation, but also cause uncoupling of NOS to produce
vasoconstrictor superoxide instead of vasodilator NO [17-18].

Therefore, the aim of the present study was to evaluate the vascular
and renal effects of several flavonoid extracts in L-NAME-treated
hypertensive rats. We have also examined some of the mechanisms
involved in their beneficial effects such as an improvement in NO
bioavailability and endothelial and vascular function, the reduction in
oxidative stress markers and the effects on cardiovascular
morphological changes.

2. Materials and Methods

2.1. Animals

All the experiments were performed in male Sprague-Dawley rats
(Harlan Lab, Barcelona, Spain) housed in a temperature controlled
environment, with 12:12-h light-dark cycle in the Animal Care Facility
of the University of Murcia (REGAES300305440012). The animals were
kept and treated according to the guidelines established by the
European Union for the protection of animals used in experiments.
(86/609/EEC). All procedures were approved by the Animal Care and Use Committee of the University of Murcia (C1310050303).

2.2. Experimential groups

Eight to nine week old rats, weighing 300-325 g, were randomized into seven groups: 1. Control (n=6), rats without any treatment; 2. L-NAME (n=6), rats receiving chronic L-NAME (N-w-nitro-L-arginine methyl ester, 10 mg/Kg/day); 3. Apigenin (A, n=6), rats simultaneously treated with L-NAME plus A (1.44 mg/Kg/day); 4. Lemon Extract (LE, n=6), rats simultaneously treated with L-NAME plus LE (2.84 mg/Kg/day); 5. Grapefruit + Bitter Orange Extracts (GBO, n=6), rats simultaneously treated with L-NAME plus GBO extract (9.28 mg/Kg/day); 6. Cocoa Extract (COE, n=6), rats simultaneously treated with L-NAME plus COE (2.52 mg/Kg/day); 7. Diosmin (D, n=6), rats simultaneously treated with L-NAME plus D (7.16 mg/Kg/day).

A summary of the main features of the flavonoids used in the present study is available as a supplemental file (table S1). The extracts selected, were by virtue of their importance in the market, sales level, etc ... being all of them extracts used as ingredients in nutritional supplements for many years. All these extracts, have been used with reasonable success in this market in the field of cardiovascular health, though, perhaps non-specifically, given the diversity of their potential mechanisms of action, and the corresponding physiological-macroscopic effects. The study used a single dose (mg/kg body weight/day) based on the usual market consumption, with a minimum adjustment to obtain dosages that supposed the same incidence in cost-dose/day (see table in supplemental file). All treatments were administered during 6 weeks, in the drinking water, except for Diosmin that was given mixed with the powdered food, in powder feeders (Tecniplast, USA). All animals had free access to a standard rat diet with a 0.5% of sodium content (104 mEq/Kg) and tap water, with or without treatments. The concentrations of the drugs were adjusted daily according to the body weight and water and food intake. All products, except L-NAME (Sigma), were kindly provided by Nutrafur SA-FRUTAROM Group. The composition of the different extracts used in this study was determined by High-Performance Liquid Chromatography (HPLC) as previously described [19-20]. The HPLC chromatograms have been also included in the supplemental file. In all extracts and purified compounds assayed, the unique active components are flavonoids. A detailed and quantitative description is provided in table 1. The rest of the components up to 100% of the extract composition was (depending on each extract): polysaccharides from the vegetable source used for the extraction (1-50%), water (3-5%), mineral salts (1-5%), pectins (1-5%) and lipids (1-2%). The molecular structures of main flavonoids are also described in table 1.

2.3. Experimental procedures

Rats were maintained in their cages up to weeks 4th and 5th when they were progressively accustomed to individual metabolic cages (Tecniplast, USA) three days a week. Then, the week 6th, after two days of adaptation, we measured food and water intake and urinary volume (diuresis) in 24 hours. The urine samples were collected and centrifuged (1000 g, 10 min) to remove solid matter and then kept at
The urinary sodium concentration was determined using a sodium electrode (Thermo Scientific Orion, USA). Sodium balance (mEq/day/100 g) was calculated as the difference between sodium intake and urinary sodium excretion and factored by body weight. Sodium intake (mEq/day) was obtained by multiplying the consumption of food per day (g/day) by sodium content of the diet (0.104 mEq/g). Urinary sodium excretion (mEq/day) was determined as the product of sodium concentration and 24-h urinary volume (ml/day).

2.3.1. Measurement of blood pressure and samples extraction

After the metabolic study was completed, the animals were anesthetized with sodium pentobarbital (5 mg/Kg, i.p.) and placed on a heated table to maintain body temperature at 37º C. A polyethylene catheter (PE-50) was placed in the right femoral artery to measure mean arterial pressure (MAP; Hewlett Packard 1280 pressure transducer and amplifier 8805D, Andover, MA) and to collect blood samples, as previously described [10-12]. Then, blood was collected into heparinized tubes and plasma was obtained by centrifugation (1,000 g, 10 min, 4º C). Thereafter, the animal was euthanized by opening the thorax. We extracted the descending thoracic aorta and placed it in a Petri dish containing oxygenated and pre-warmed Krebs solution for the vascular reactivity study. Finally, kidneys, heart, and abdominal aorta were also removed. All samples were frozen (-80º C) and a small portion was also fixed with a 10%-formalin solution for pathology studies.

2.3.2. Vascular reactivity study

The thoracic aorta was cleaned of adhering fat and connective tissue; care was taken not to disrupt vascular endothelium, as previously described [21]. Then, the aorta was cut into four rings (3-4 mm) and mounted in 10 ml organ baths (organ bath system LE 01004, Panlab, Barcelona, Spain) containing a physiological Krebs solution with the following composition (mM): NaCl, 118; KCl, 4.7; CaCl₂, 2.5; MgSO₄, 1.2; NaHCO₃, 25; KH₂PO₄, 1.2; edetate calcium disodium, 0.026; and glucose, 5.6. The Krebs solution was maintained at 37º C and continuously bubbled with a mixture of 95% O₂ and 5% CO₂. The rings are connected to isometric force transducers (TRI202P, Panlab) to detect tension changes that were acquired and analyzed with a data acquisition system (AD Instrument, Oxford, UK) consisting of a bridge amplifier (FE228), a data acquisition hardware (PowerLab 8/30) and a software (LabChart 6.0). Aortic rings were equilibrated for at least 45 min at a resting tension of 2 g before any specific experimental protocol was initiated. During this period, the bathing solution was replaced every 15 min and, if needed, the basal tone readjusted to 2 g. After the stabilization period, the aortic rings were constricted using a cumulative dose–response curve to phenylephrine (Phe, 10⁻⁹–10⁻⁴ mol/L), administered in 0.1 ml bolus. Then, the rings were washed (usually 2-3 times) until the resting tension was reached again and a second stabilization period of 30 min was allowed. To evaluate the vasodilator responses to acetylcholine (Ach), the aortic rings were pre-contracted with a submaximal dose of Phe (10⁻⁶ mol/L). Once a stable plateau was reached, a cumulative dose–response curve to the Ach (10⁻⁹–10⁻⁴ mol/L) was performed to assess the endothelium-dependent vasodilatation. Thereafter, the rings were frequently washed once again
196 and a third stabilization period of 30 min was permitted and followed by
197 an incubation period of 30 min with the NOS-inhibitor L-NAME (10^-4 M)
198 to inhibit NO synthesis. Next, a cumulative concentration-response
curve to Ach was again performed, to evaluate the role of NO in the
199 endothelium-dependent vasodilatation. Finally, we added a single dose
200 of SNP (10^-4 M) to test the independent vasodilator responses and the
201 functionality of the smooth muscle. The responses to PHE are
202 expressed in grams and the relaxation to Ach and SNP as the
203 percentage of the maximal PHE effect. Stock solutions of these drugs
204 were prepared in distilled water and maintained frozen at -20º C.
205 Working solutions were prepared daily in Krebs solution. Drug
206 concentrations are expressed as final bath concentrations. All reagents
207 and vasoactive compounds were purchased from Sigma-Aldrich and
208 Panreac (Spain).
209
210 2.4. Analytical procedures
211 TBARS (thiobarbituric acid reactive substances) in plasma and
212 kidney tissue were determined as a measure of lipid peroxidation by
213 using a colorimetric method [17]. Briefly, 0.5 ml of potassium phosphate
214 buffer (0.1 M, pH 7.4) was added to 100 µl of plasma sample mixed or
215 50 µl of kidney tissue lysate. After mixing, 1 ml of reagent solution [1
216 mmol/l deferoxamine mesylate, 7.5% (w/v) trichloroacetic acid, 0.25
217 mol/lHCl and 0.37%thiobarbituric acid] was added and the mixture was
218 vortex-mixed, covered with aluminium foil to avoid evaporation and
219 heated at 90º C for 15 minutes in a dry block heater (Heatblock II,
220 VWR, Thorofare, NJ USA). After the mixture had returned to room
221 temperature, TBARS from standards (prepared from 1,1,3,3-
222 tetraethoxypropane) and samples were extracted into 1 ml of butanol.
223 After a vigorous vortex-mixing and a brief centrifugation (1000 g for 5
224 min), the absorbance of the butanol layer was read at 532 nm in a
225 spectrophotometer (Eppendorf Biophotometer Plus, Hamburgo,
226 Germany), and the value was expressed as nmol/mL of plasma or
227 nmol/mg of kidney protein. The protein concentration was measured in
228 the urine and lysates using the bicinchoninic acid based-method
229 (Sigma). The plasma and urinary excretion of nitrite was determined by
230 using the Griess reaction. Briefly, sample volumes of 100 µL were mixed
231 with 50 µL of 1% Sulfanilamide in 5% Potassium Phosphate. Then 50 µL
232 of 0.1% N-(1-Naphthyl) Ethyl-Enediamine dihydrochloride was added
233 and incubated for 15 minutes. The nitrite concentration was quantified
234 in a spectrophotometer at 540 nm against the standards and
235 subtracting a blank from each individual sample. The final
236 concentration was expressed in µg/mL for plasma or µg/day for urine
237 samples.
238 2.5 Histopathological Analysis
239 Aortic, cardiac and renal tissue samples were fixed in 10% buffered
240 formaldehyde and then processed, embedded in paraffin and sectioned
241 (4 µm) as previously reported [22-23]. Transversal kidney, ventricular
242 heart and thoracic and abdominal aorta sections were stained with
243 hematoxylin-eosin and periodic acid-Schiff stain. The morphological
244 study was done by a pathologist in blinded randomized sections of the
245 tissues, with light microscopy and using the most appropriate stain for
246 each lesion. The histo-morphometric measurements were performed
with the software ImageJ 1.47 (NIH, http://rsb.info.nih.gov/ij/). In the aorta, wall thickness was measured in three different, randomly selected regions, and also three times in each region. In the heart, different parameters of cardiovascular injury were analyzed in three transversal sections at different levels of the ventricle: 1) the interventricular septum thickness was assessed in the middle central region of the cardiac cavities; 2) the number of all cardiac infarcts was counted in the three slides of each heart to evaluate the absence (0) or presence (1) of cardiac infarcts; 3) hyaline arteriopathy and fibrinoid necrosis were also measured in a dichotomous manner depending on the absence (0) or presence (1) of these alterations; and 5) the relation between luminal diameter and wall thickness in main and intramural coronary arteries was obtained from 5 measurements of each artery.

In the kidney, we evaluated the main alterations observed in transversal sections that included cortex and medulla. These were: 1) the absence or presence of hyaline arteriopathy in all the arteries seen in the whole section; 2) the relation between luminal diameter and wall thickness in the main renal artery or principal branches (if the first is missing); and 3) the absence (0) or presence (1) of tubular cast/cylinders in the cortical and medullary region from the entire kidney section. We did not observe any appreciable glomerular lesions and only other scarce vascular and tubular lesions. Finally, in order to estimate the overall vascular injury, we scored (0) if only one of the two organs, heart or kidney, was damaged and (1) if both organs were affected in the same animal.

2.6. Statistical Methods

Data are presented as the mean ± standard error. Differences between groups were compared mainly by one-way analysis of variance (ANOVA). In the vascular reactivity experiments, the values of EC$_{50}$ were calculated from the individual curves and expressed as the negative logarithm (pEC$_{50}$). Differences were considered statistically significant at a P level lower than 0.05.

3. Results

Body weight and hematocrit of all the experimental groups are listed in Table 1. After the six weeks study period, L-NAME rats showed significantly lower body weight compared to control rats and all the flavonoid treatments showed a tendency to a normal body weight when compared to controls, especially in the case of apigenin. The hematocrit of all experimental groups was very similar, without significant differences between them.

Table 1. Body weight and hematocrit values in the experimental groups.

<table>
<thead>
<tr>
<th></th>
<th>Body weight (g)</th>
<th>Hematocrit (%)</th>
<th>Food intake (g/24h)</th>
<th>Water intake (ml/24h)</th>
<th>Diuresis (ml/24h)</th>
<th>Natruiresis (mEq/24h)</th>
<th>Sodium balance (mEq/24h/100g)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>429.73 ± 6.36</td>
<td>47.38 ± 0.47</td>
<td>23.05 ± 0.68</td>
<td>35 ± 0.54</td>
<td>12.83 ± 1.46</td>
<td>0.41 ± 0.08</td>
<td>0.15 ± 0.05</td>
</tr>
<tr>
<td>L-N</td>
<td>345.73 ± 22.29*</td>
<td>47.20 ± 1.20</td>
<td>21.1 ± 1.21</td>
<td>31.25 ± 4.7</td>
<td>7.85 ± 1.69</td>
<td>0.22 ± 0.06</td>
<td>0.43 ± 0.11*</td>
</tr>
<tr>
<td>A</td>
<td>426.90 ±11.46</td>
<td>50.67 ± 2.38</td>
<td>20.83 ± 0.63</td>
<td>30 ± 0.22</td>
<td>17.37 ± 3.85</td>
<td>0.47 ± 0.02</td>
<td>0.04 ± 0.05</td>
</tr>
<tr>
<td>Group</td>
<td>pEC_{50} (mol/l)</td>
<td>Maximal contraction (g)</td>
<td>Maximal relaxation (%)</td>
<td>After acute L-NAME</td>
<td>Maximal relaxation (%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>-----------------</td>
<td>------------------------</td>
<td>-----------------------</td>
<td>-------------------</td>
<td>------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>-6.45 ± 0.086</td>
<td>2.37 ± 0.15</td>
<td>82.70 ± 2.50</td>
<td>27.38 ± 6.54</td>
<td>99.38 ± 1.62</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-N</td>
<td>-6.83 ± 0.064*</td>
<td>2.54 ± 0.12</td>
<td>19.88 ± 4.14*</td>
<td>4.55 ± 2.70*</td>
<td>89.71 ± 2.03*</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: C, control; L-N, N(G)-Nitro-L-arginine methyl ester treated group; A (Apigenin); LE (Lemon extract); GBO (Grapefruit + bitter orange extract); COE (Cocoa extract), and D (Diosmin). Data are mean ± S.E.M. *, p<0.05 vs Control; +, p<0.05 vs L-NAME.

3.1 Blood pressure and urinary variables

Mean arterial pressure (MAP) data are shown in figure 1. Oral administration of L-NAME for six weeks caused a significant increase in mean arterial pressure. Treatments with A, LE and GBO extracts significantly reduced MAP associated with the chronic inhibition of NOS. Diuresis and natriuresis were not statistically different in the experimental groups (table 1), although the L-NAME group had a tendency towards lower values. Regarding sodium balance, a greater sodium balance was found in the L-NAME treated group, indicative of sodium retention. The groups treated with flavonoids showed no statistical differences in sodium balance when compared to the control or L-NAME groups, although the group treated with apigenin showed a lower sodium balance than the L-NAME group (Fig 2).

Table 2. Contractile response to phenylephrine and maximal relaxation to acetylcholine and sodium nitroprusside in the experimental groups.
3.2 Vascular function

Dose-response curve to Phe was significantly shifted upwards in the animals chronically treated with L-NAME (Fig 3) and EC\textsubscript{50} values were significantly decreased from 3.90 ± 0.72 in controls to 1.54 ± 0.22 (table 2). The responses of the groups treated with L-NAME and flavonoids were not significantly different but GBO, COE, and D showed also a lower EC\textsubscript{50} than that of the control group. Maximal Ach-induced vasodilatation (Fig 4) was significantly reduced in aortic rings from L-NAME hypertensive rats compared to control rats (table 2). The relaxation to Ach improved in the aorta from rats treated with A, LE and COE but the relaxation still remained lower than in control rats. After administration of acute L-NAME (10^{-4} mol/l) to these aortic rings (Fig 5), the relaxant responses were further reduced, but there were some residual responses in the A and COE groups.
Vasorelaxation in response to SNP was slightly but significantly lower in the flavonoid-untreated L-NAME rats when compared with the control rats. SNP induced similar responses in all flavonoid-treated groups, although A showed a significantly increased relaxation as compared to the untreated L-NAME group (table 2).

Table 3. Measurements of TBARS, nitrite and proteinuria in the experimental groups.

<table>
<thead>
<tr>
<th></th>
<th>Plasma TBARS (nmol/ml)</th>
<th>Kidney TBARS (nmol/mg prot)</th>
<th>Urine TBARS (nmol/mg prot/24h)</th>
<th>Plasma Nitrite (µg/ml)</th>
<th>Urinary excretion of nitrite (µg/24h)</th>
<th>Urinary protein excretion (mg/24h/ Kg bw)</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>1.5 ± 0.3</td>
<td>1.5 ± 0.1</td>
<td>576 ± 65</td>
<td>1.25 ± 0.18</td>
<td>11.83 ± 1.31</td>
<td>367.58 ± 11.19</td>
</tr>
<tr>
<td>L-N</td>
<td>1.8 ± 0.2</td>
<td>2.0 ± 0.3*</td>
<td>437 ± 37</td>
<td>1.02 ± 0.05</td>
<td>6.39 ± 0.46*</td>
<td>468.60 ± 39.52*</td>
</tr>
<tr>
<td>A</td>
<td>1.7 ± 0.3</td>
<td>1.6 ± 0.2</td>
<td>512 ± 46</td>
<td>1.26 ± 0.09</td>
<td>13.40 ± 1.82+</td>
<td>360.64 ± 40.15</td>
</tr>
<tr>
<td>LE</td>
<td>1.6 ± 0.3</td>
<td>1.1 ± 0.3</td>
<td>488 ± 69</td>
<td>0.88 ± 0.04</td>
<td>11.02 ± 1.63</td>
<td>373.50 ± 61.90</td>
</tr>
<tr>
<td>GBO</td>
<td>1.3 ± 0.2</td>
<td>1.6 ± 0.0</td>
<td>458 ± 51</td>
<td>1.02 ± 0.02</td>
<td>9.05 ± 1.64</td>
<td>426.51 ± 18.81*</td>
</tr>
<tr>
<td>COE</td>
<td>1.3 ± 0.2</td>
<td>1.4 ± 0.3</td>
<td>482 ± 108</td>
<td>0.99 ± 0.11</td>
<td>14.12 ± 4.97</td>
<td>498.51 ± 67.17</td>
</tr>
<tr>
<td>D</td>
<td>1.4 ± 0.1</td>
<td>1.5 ± 0.1</td>
<td>546 ± 78</td>
<td>1.11 ± 0.12</td>
<td>12.02 ± 1.03+</td>
<td>420.13 ± 75.24</td>
</tr>
</tbody>
</table>

Data are mean ± S.E.M. Abbreviations as in table 1. *, p<0.05 vs control, +, p<0.05 vs L-NAME

3.3 Effect of flavonoid extracts on Oxidative Stress Status

Values of TBARS, nitrite and urinary protein excretion are shown in table 3. Regarding TBARS, a significant increase was found only in the kidneys of the animals chronically treated with L-NAME as compared with controls. The rest of the groups did not show significant differences. Also, nitrite urinary excretion was significantly lower in the L-NAME group, but apigenin and diosmin significantly elevated it as compared to the L-NAME-treated group. There were no significant changes in proteinuria in the experimental groups, except in the L-NAME-treated group, showing enhanced urinary protein excretion, as compared with the control.

Table 4. Histopathological results of the heart and aorta.

<table>
<thead>
<tr>
<th># infarcts</th>
<th>HA</th>
<th>FN</th>
<th>LWR</th>
<th>IVS</th>
<th>TAT</th>
<th>AOT</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>0.0</td>
<td>0.0</td>
<td>0.0</td>
<td>3.01±0.58</td>
<td>2.41±0.03</td>
<td>131.9±3.1</td>
</tr>
<tr>
<td>L-N</td>
<td>4.33±3.84</td>
<td>0.67±0.33</td>
<td>0.67±0.33</td>
<td>2.22±0.95</td>
<td>3.20±0.10*</td>
<td>176.3±4.2*</td>
</tr>
<tr>
<td>A</td>
<td>0.67±0.67</td>
<td>0.33±0.33</td>
<td>0.0</td>
<td>2.39±0.44</td>
<td>2.62±0.25</td>
<td>178.0±14.8*</td>
</tr>
<tr>
<td>LE</td>
<td>3.33±3.33</td>
<td>0.0</td>
<td>0.0</td>
<td>2.97±0.10</td>
<td>2.71±0.16</td>
<td>141.4±2.4†</td>
</tr>
<tr>
<td>GBO</td>
<td>3.67±1.86</td>
<td>0.33±0.33</td>
<td>0.33±0.33</td>
<td>1.99±0.40</td>
<td>2.42±0.22†</td>
<td>157.5±8.5*</td>
</tr>
<tr>
<td>COE</td>
<td>2.67±1.45</td>
<td>0.0</td>
<td>0.0</td>
<td>2.49±0.06</td>
<td>3.11±0.36</td>
<td>155.9±5.4†</td>
</tr>
</tbody>
</table>
Data are mean ± S.E.M. Abbreviations as in table 2. HA, hyaline arteriopathy; FN, fibrinoid necrosis; LWR, lumen to wall ratio of coronary arteries; IVS, interventricular septum (µm); TAT, thoracic aorta wall thickness (µm); AOT, abdominal aorta wall thickness (µm); *, p<0.05 vs control; †, p<0.05 vs L-NAME.

<table>
<thead>
<tr>
<th></th>
<th>D</th>
<th>4.00±4.00</th>
<th>0.33±0.33</th>
<th>0.33±0.33</th>
<th>2.74 ± 0.94</th>
<th>2.22 ± 0.08†</th>
<th>164.3 ± 7.2*</th>
<th>116 ± 4.4†</th>
</tr>
</thead>
</table>

3.4 Histopathology results

The analysis of the heart (table 4 and figure 6) revealed that the L-NAME-treated group had more infarct zones, hyaline arteriopathy and fibrinoid necrosis as compared to the untreated control group. The treatments tend to decrease all these parameters. Wall-lumen ratio of coronary arteries was decreased in the L-NAME untreated rats when compared with control and, again, most treatments showed a tendency to increase the values but without being statistically significant. Interventricular heart septum thickness was significantly higher in the L-NAME-untreated animals compared to control rats and all treatments showed lower values, but only the decrease was significantly different in the groups treated with GBO and D. With respect to the thickness of the abdominal and thoracic aorta, L-NAME-treatment significantly

Figure 6. Representative microphotographs of heart lesions. Upper left: intramyocardial artery (A) of a control non-treated rat (no morphological alterations, PAS, 10x); upper right: hyaline arteriopathy (HA) in a coronary artery of L-NAME-treated rat (PAS, 10x); lower left: intense vascular damage with inflammatory infiltrate (II) and myocardocytes lesions in a L-NAME-treated rat heart (PAS, 10x); lower right: fibrinoid necrosis (FN) in a coronary artery of L-NAME-treated rat (PAS, 10x).
increased it and LE and COE treatments reduced it to levels comparable to controls.

Table 5. Histopathological results of the kidney.

<table>
<thead>
<tr>
<th></th>
<th>LWR</th>
<th>HA</th>
<th>TC</th>
<th>Combined vascular damage</th>
</tr>
</thead>
<tbody>
<tr>
<td>C</td>
<td>1.80±0.05</td>
<td>0</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>L-N</td>
<td>1.72±0.32</td>
<td>0.67±0.33</td>
<td>0.33±0.33</td>
<td>0.67±0.33</td>
</tr>
<tr>
<td>A</td>
<td>1.85±0.27</td>
<td>0</td>
<td>0.33±0.33</td>
<td>0</td>
</tr>
<tr>
<td>LE</td>
<td>1.07±0.19</td>
<td>0.17±0.17</td>
<td>0.50±0.29</td>
<td>0</td>
</tr>
<tr>
<td>GBO</td>
<td>2.97±1.07</td>
<td>0.33±0.33</td>
<td>0.37±0.33</td>
<td>0.33±0.33</td>
</tr>
<tr>
<td>COE</td>
<td>1.63±0.45</td>
<td>0.33±0.33</td>
<td>1.00±0.00</td>
<td>0</td>
</tr>
<tr>
<td>D</td>
<td>1.53±0.09</td>
<td>0.33±0.33</td>
<td>0.67±0.33</td>
<td>0.33±0.33</td>
</tr>
</tbody>
</table>

Data are mean ± S.E.M. Abbreviations as in table 2. HA, hyaline arteriopathy; TC, tubular cylinders.

Regarding the kidney (table 5 and figure 7), we found no significant differences between groups in any of the measured parameters.
although for HA, all treated groups showed values lower to the L-NAME group, observing in the case of apigenin, a complete recovery. However, the presence of tubular cylinders was still evident in all the treated groups. Finally, when evaluating overall vascular damage (heart and kidney together), it seems that most treatments reduced it, being A, LE and COE those showing the lower vascular damage values, similar to the controls.

4. Discussion

The results of the present study show that some flavonoids, especially A, LE, and GBO, at the doses studied, reduced the elevated blood pressure levels reached by chronic L-NAME administration. This effect was accompanied, in the case of apigenin, with a normalization of the reduced vascular reactivity to vasoconstrictors and a lower sodium retention. An enhanced vasodilator ability, related to an increased production of NO, was also observed together with beneficial changes in the histopathological parameters in heart and kidney.

The chosen dose of each of the treatments responds to an objective criterion of a possible later use in humans. The doses ingested daily by the animals are very low compared to those used in other studies with similar compounds. Moreover, doses much greater than those applied in human therapy are usually used (5, 14, 18, 24). In addition, we needed doses that could be used with economic realism in the case of a future application to the field of pharmacy or the so-called nutritional supplements. In all cases, the doses used would cost 2-3 cents of € per day, a value normally established as a reference in this type of products.

L-NAME-treated rats showed a lower weight than the controls and the treatment with flavonoids prevented the decrease in body weight during concomitant treatment with L-NAME (Table 2). This effect occurred despite a lower level of food intake in these flavonoid+L-NAME treated groups compared to L-NAME alone. This effect is probably related to the anti-hypertensive effect of these treatments, as other studies have shown with more specific treatments, such as blockade of the renin angiotensin system [12], a similar effect on body weight. However, other mechanisms such as the role of neuronal NOS in hypothalamus, the central regulator of food intake, may be involved. It is possible that flavonoids, by increasing neuronal NO bioavailability, may prevent the decrease in body weight. Thus, early studies showed that competitive inhibitors of NOS produced an L-arginine-reversible decrease in food intake [25], a result not found in the present studies, since the decrease in body weight was accompanied by a decrease in food intake. This contradiction could be explained by flavonoid effects on energy expenditure and digestive efficiency, as it has been recently demonstrated with naringenin [26].

Chronic NOS inhibition leads to sodium retention, also found in the present results, since NO is diuretic and natriuretic and promotes pressure natriuresis [10-11]. Although the treatments showed a tendency to improve sodium excretion (Figure 2), there were no significant differences between groups.
Many studies have reported a reduction in blood pressure following the consumption of flavonoid-rich products. In vitro studies have reported that flavonoids such as genistein, quercetin, and (-)-epicatechin regulated (directly or indirectly) NO production in isolated vessels or cultured endothelial cells [8, 24, 27]. However, most of them do not establish a clear dose-structure-activity relationship.

Our results agree with those studies showing that some of the treatments achieved a significant reduction of MAP, specifically GBO and LE and, at a lesser level, A and D (Figure 3). We hereby suggest that there are structural elements in the flavonoid molecular skeleton that are likely to achieve this BP lowering effect. The order of structural preference in the reduction of BP was similar when comparing the effectiveness of active flavonoids with that of a flavanone-glycoside predominance in the molecular structure, such as GBO and LE. A lower level would be that of flavone configurations, A and D, which are characterized by a double bond between carbons 2 and 3 conjugated with the C-4 carbonyl group (table 1). It is also possible that the B-ring structure has some responsibility in this antihypertensive effect, since the structure 4’-hydroxy flavone/flavanone (A and naringin in GBO) seems to be more active than 3’-hydroxy-4’-methoxy flavone (D). The B-ring model 3’, 4’-dihydroxy (LE), thus, the catechol group is probably the most active structure at an equal concentration. Moreover, this structure seems to be essential for the inhibitory effect on angiotensin-converting enzyme activity, which plays a key role in the regulation of arterial blood pressure, independent of the presence of the flavone or flavanone flavonoid structure [20].

Future studies will be necessary to further define the structure-activity-dosage relationship of these drugs.

A mechanism responsible for the increase of BP during chronic L-NAME-treatment is associated with NO deficiency. Lower NO levels allow a greater expression of vasoconstrictors and attenuation of vasorelaxation in different vascular beds, as the present results confirm by the decrease in the EC50 of the L-NAME-treated group. As observed (table 3), only apigenin (4’-hydroxy flavone) normalized the altered EC50 of these animals, although there was also some improvement in the LE group (3’, 4’-dihydroxy flavanone). This lower vasoconstrictor ability may be related to an increased production of some vasodilators, since the Ach-induced vasodilation was also improved by apigenin (Table 3, Figures 4 and 5), specially in the group where NO was acutely inhibited. Interestingly, an NO-independent component seems to participate also in the vasodilatation improvement showed by A and COE since a residual vasorelaxation was still observed after acute L-NAME inhibition. This vascular relaxation promoted by flavonoids could partly explain the ability of these substances to reduce blood pressure.

The results for A (4’-hydroxy flavone) and the significant lower efficacy of D (3’, 4’-methoxy flavone-7-O-glycoside), suggest that the combination of a double bond between carbons C2=C3 (flavonoid-planar structure) as a glycon form (without sugar radicals) and with a B-ring type 4’-hydroxy could be of importance to produce vascular relaxation and the improvement of eNOS expression. Moreover, it appears that a small molecular volume is favorable for a given flavonoid.
to become active [28-29]. Our data are thus in agreement with previous findings from other studies [30-32].

Other mechanisms have been suggested to explain the increased endothelial NO bioavailability promoted by flavonoids. Several studies have shown that a regular consumption of flavonoids or flavonoid-rich foods can significantly improve the oxidative status as well the endothelial function [8]. To clarify and understand this, it is important to note that the antioxidant activity of flavonoids is not only related to a simple activity as oxygen free radical scavengers do. Other mechanisms that flavonoids use to regulate the oxidative status are related to an activity as epigenetic agents (increasing the expression of endogenous antioxidant enzymes as superoxide dismutase, glutathione,...) and/or as inhibitors of pro-oxidative enzymes (cyclooxygenase, lipooxygenase,...) from the arachidonic pathway (33-36). In the present study, we detected a significant increase in ROS levels, as measured as TBARS (MDA: malonyl dialdehyde), in kidney tissue. It is important to note that MDA, an index of lipid peroxidation, has been found to be increased by L-NAME treatment [12, 37-38]. It is likely that the reduction in kidney TBARS, observed in some of the flavonoid-treated groups (Table 4), is also contributing to the normalization of blood pressure. Although the results obtained do not show statistical significance, it may be interesting to consider that the treatments with a greater specific antioxidant efficacy are those having flavonoids with B-ring catechol structure (3', 4'-dihydroxy), LE (eriocitrin) and COE (catechin compounds). The urinary nitrite excretion levels (Table 4) of the L-NAME-treated rats was lower than that of the control group. In the treatment groups, only A and D, thus flavonoids with flavone structure, appear to generate a greater production of NO metabolites. Lower efficacy is shown by LE and COE, the catechol-containing flavonoid extracts.

It is known that the chronic deficit of NO usually results in an elevation of systemic blood pressure, an increase in glomerular capillary pressure and a reduction in the coefficient of ultrafiltration. These changes are associated with the presence of proteinuria and the development of glomerulosclerosis [39], as our data show (table 4). The flavonoids treatments show, for most of them, a reduction in proteinuria, thus indicating a reduction of renal glomerular damage. The behavior of A and LE is remarkable since they show values similar to those of the control group.

The metabolic and hemodynamic changes of L-NAME hypertension are also associated with the development of structural abnormalities, such as left ventricular hypertrophy, cardiac fibrosis, necrosis and protein remodeling, as well as with vascular wall hypertrophy [12], also shown in the present results. NO deficiency may thus result in increased monocyte and platelet adhesion, which by releasing growth factors would contribute to the thickening of the vascular wall. The proliferation was limited to the media, which is in agreement with the findings of others [40-42]. Although the lesions had a tendency to an improvement in the flavonoid-treated groups, no significant effects were seen in most of them. Only A, LE, and COE showed a beneficial effect in the aortic thickness. Regarding the renal structural changes, although
we found no significant differences between groups, all treated groups showed values lower than the L-NAME group. Finally, when the overall vascular damage (heart and kidney together) was evaluated, it seems that most treatments reduced it, being A, LE, and COE those showing the lower vascular damage values, similar to the controls.

5. Conclusions

Our results suggest that the flavonoids included in this study, and already present in the market as nutritional supplements, may be used as food ingredients with potential therapeutic benefit in arterial hypertension. Further studies are necessary to elucidate the mechanisms involved in their antihypertensive effect, including an evaluation of the dose-activity relationship in order to determine the molecular structures most active. In any case, our results agree with previous findings [42] and suggest that the blood pressure lowering effect of these flavonoids may be related to a combination of vasodilator and antioxidant actions.

Supplementary Materials: Table S1: Characteristics of flavonoids used.

Acknowledgments: This report was supported by a grant from the National Spanish R&D Program CENIT of the Spanish Ministry of Science and Technology denominated “Industrial research diets and food with specific features for the elderly”, CEN-20091006; Acronym: SENIFOOD. We have not received funds for covering the costs to publish in open access.

Author Contributions: “J.C., M.C.O. and J.G-E. conceived and designed the experiments; M.D.P. performed most of the experiments; P.R. and N.M.A. performed the vascular reactivity experiments; F.O. contributed the histopathology; J.G-E wrote the paper.

Conflicts of Interest: The authors declare no conflict of interest.

References


